TP53 突变 – Medxy AI

First-line Ibrutinib Plus Venetoclax in Nonblastoid Mantle Cell Lymphoma: Efficacy and Safety in Older Adults and TP53-Mutant Patients

By MedXY 09/22/2026

The phase 3 SYMPATICO trial demonstrated that first-line combination therapy with ibrutinib and venetoclax yields high complete response rates and durable remissions in patients ≥65 years or with TP53 mutations suffering from nonblastoid mantle cell lymphoma.

Hematology-Oncology news

Decoding Chromosome 5q Deletion: Driving Aneuploidy Evolution and Therapeutic Strategies in Complex Karyotype Myeloid Neoplasms

By MedXY 09/01/2026

Chromosome 5q deletions combined with TP53 mutations drive stepwise aneuploid evolution in complex karyotype AML, unveiling shared transcriptional vulnerabilities exploitable by targeted therapies like BCL2 inhibition with venetoclax.

Hematology-Oncology news

TP53-Mutated Clonal Hematopoiesis Drives Pro-Inflammatory Phenotype and Predicts Poor Outcomes After CAR T-Cell Therapy

By MedXY 08/26/2026

TP53-mutant clonal hematopoiesis in CAR T-cell recipients is linked to a pro-inflammatory state, cytopenias, and worse survival, highlighting the importance of tailored monitoring strategies in this high-risk group.

Hematology-Oncology news

CPX-351 Benefit in AML is Driven by Myelodysplasia-Related Mutations: Insights from a Phase 3 Molecular Re-analysis

By MedXY 02/17/2026

A molecular re-evaluation of the pivotal CPX-351 phase 3 trial reveals that its survival benefit is selectively confined to patients with myelodysplasia-related mutations (AML-MR), with no significant advantage over standard 7+3 induction in TP53-mutated or other molecular subgroups.